Skip to main
STE

STERIS (STE) Stock Forecast & Price Target

STERIS (STE) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Steris is well-positioned for future growth with strong organic revenue growth, consistent margin expansion, and supportive capital allocation strategies. The company's focus on healthcare services and biopharma manufacturing, as well as its global leadership in contract sterilization, make it a reliable and essential player in the medical technology industry. Additionally, the company's recent complementary acquisitions and plans for new facilities and a share buyback program demonstrate a commitment to long-term growth and shareholder value.

Bears say

Steris is a global leader in contract sterilization services, but recent trends in healthcare spending and potential regulatory actions from the FDA may impede the company's stock performance. The company is making a significant investment in a new facility in North Carolina, but the benefits of this investment may not be seen for multiple years. There are also several factors impacting operating margin trends, including potential cost increases related to energy and raw materials, and the company's goal of sustainable annual margin expansion of ~50 bps may be challenging to achieve in the current market conditions.

STERIS (STE) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STERIS (STE) Forecast

Analysts have given STERIS (STE) a Buy based on their latest research and market trends.

According to 3 analysts, STERIS (STE) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $271.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $271.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STERIS (STE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.